Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
Wainua | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Active | ||
Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Wegovy | semaglutide | Weight management | Do not reimburse | Complete | ||
Wegovy | semaglutide | weight management | Pending | |||
Welireg | belzutifan | von Hippel-Lindau disease-associated tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
Welireg | belzutifan | advanced renal cell carcinoma (RCC) | Pending | |||
Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
Winlevi | clascoterone | Acne vulgaris | Active | |||
Winrevair | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Reimburse with clinical criteria and/or conditions | Active | ||
Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Xalkori | Crizotinib | Advanced Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Xalkori | Crizotinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Xalkori | Crizotinib | First Line ALK Positive Advanced NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. | Reimburse with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban (granules for oral suspension) | Venous Thromboembolic Events | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Xarelto | Rivaroxaban | Venous thromboembolism, prevention | N/A | Complete | ||
Xarelto | Rivaroxaban | Atrial fibrillation, stroke prevention | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | Complete | |||
Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
Xcopri | cenobamate | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete |